IL6 and systemic sclerosis: The contribution of AP-1/c-FOS signalling to the SSc-IgG-driven IL-6 release was confirmed by the observation that the effect of SSc-IgG was significantly reduced by SR-11302, a specific AP-1 inhibitor (Figure 6E) and by silencing c-FOS with specific siRNA (Figure 6F).